Market Overview

Citigroup Says Actavis Is Now Worth $360 Per Share (And It's A Buy)

Share:

In a report published Tuesday, Citigroup analyst Liav Abraham commented on a recent meeting with Actavis plc's (NYSE: ACT) senior management team in London that increased his confidence in a "swift and successful" integration of Allergan, Inc.

Abraham noted that key growth opportunities for the joint company remain Botox, dermal fillers, glaucoma, Linzess, Bystolic. The analyst added that he is "increasingly comfortable" in the execution of the Namenda switch and of Actavis' pricing/rebating strategy to mitigate the declines of this franchise moving forward.

Abraham also commented on the "bright sparks" in the combined pipeline portfolio that point to several "overlooked opportunities" in areas of competence, including GI (relamorelin), ophthalmology (AGN-195263 in MGD, bimatoprost sustained release), and women's health (Esmya).

"While the focus in the specialty pharma space remains on M&A, we continue to favor names with longer term durable assets and pipeline opportunities to drive organic growth," Abraham wrote.

The analyst concluded by projecting the closing of the acquisition is imminent and that pipeline catalysts in 2015 will highlight the organic growth of the combined entity.

Shares remain Buy rated with a price target raised to $360 from a previous $325.

Latest Ratings for ACT

DateFirmActionFromTo
Jun 2015Raymond JamesInitiates Coverage onOutperform
May 2015Deutsche BankMaintainsBuy
May 2015SusquehannaMaintainsPositive

View More Analyst Ratings for ACT
View the Latest Analyst Ratings

 

Related Articles (ACT)

View Comments and Join the Discussion!

Posted-In: BOTOX Bystolic Citigroup GI Liav AbrahamAnalyst Color Price Target Analyst Ratings

Latest Ratings

StockFirmActionPT
TSLAJP MorganMaintains125.0
INTCTruist SecuritiesMaintains64.0
FBTruist SecuritiesMaintains320.0
GSCitigroupMaintains370.0
AAPLCowen & Co.Maintains153.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com